1. Introduction {#sec1-genes-08-00095}
===============

The discovery of the RNA interference pathway in 1998 and the widespread gene regulatory influences exerted by microRNAs (miRNAs) and other non-coding RNAs (ncRNAs) have certainly expanded the level of intricacy present for the development of any single physiological phenotype \[[@B1-genes-08-00095]\]. Such phenotypes can include clinical conditions of either an acute or a chronic nature. Undoubtedly, cancer best symbolizes clinical conditions relying on multifactorial influences for its development. Furthermore, the clinical presentation of any specific cancer condition in the patient can vary to great extents, depending on multiple tumour characteristics such as the degree of invasiveness, aggressiveness and angiogenesis. However, one of the most crucial cancer phenotypes that pose a major challenge to current conventional chemotherapeutic measures is the ability of the tumour to withstand the pharmacological effects of multiple cancer chemotherapy drugs, typically described as chemoresistance.

Since the influences of ncRNAs in the main facets of cancer development are described in great detail within the scientific literature, this review specifically places a spotlight on the emerging global research efforts that (in the authors' opinion) most effectively recognize the growing link pertaining to non-coding RNA activities with the regulation of cancer chemoresistance properties \[[@B2-genes-08-00095],[@B3-genes-08-00095],[@B4-genes-08-00095],[@B5-genes-08-00095],[@B6-genes-08-00095]\].

2. Cancer Chemoresistance Manifestations and Development Mechanisms {#sec2-genes-08-00095}
===================================================================

Tumours bearing a chemoresistance phenotype can irrevocably thwart the prognosis of the cancer patient, particularly when such characteristics evolve in relapse of the disease. This chemoresistance phenotype has two distinct development mechanisms, leading to the existence of innate and acquired chemoresistance phenotypes \[[@B7-genes-08-00095]\].

Innate chemoresistance refers to the scenario that an individual tumour can inherently possess unique genetic characteristics that render the tumour to withstand single (or multiple) chemotherapeutic agents, through various influences on drug cytotoxicity circumvention pathways, as described below \[[@B7-genes-08-00095]\].

In the case of acquired chemoresistance properties, the link between such cancer relapse phases and multi-drug resistant (MDR) tumours is predominantly due to the regular exposure of the tumour to conventional chemotherapeutic cyclical administration \[[@B7-genes-08-00095]\]. This essentially drives the tumour to evolve at the genetic level to a variant having increased withstanding potential against such conventional chemotherapeutic agents \[[@B7-genes-08-00095]\].

Since this article focuses specifically on the links identified so far between miRNAs/lncRNAs and cancer chemoresistance properties, it is important to highlight the main recognized mechanisms by which tumours can develop multi-drug resistance against conventional chemotherapeutic agents.

By far the most important and characterised mechanism for the emergence of cancer chemoresistance properties is the employment of drug efflux pumps that actively remove multiple drugs from the tumour cell cytoplasm, including conventional chemotherapeutic agents and eventually leading to MDR \[[@B8-genes-08-00095],[@B9-genes-08-00095],[@B10-genes-08-00095],[@B11-genes-08-00095],[@B12-genes-08-00095]\]. The key molecular players involved in drug efflux processes are primarily the ATP-dependent binding cassette (ABC) transporters such as ABCG2, ABCB1 (multidrug resistance 1 gene/P-glycoprotein) and ABCC1 (multidrug resistance-associated protein 1) \[[@B8-genes-08-00095],[@B9-genes-08-00095],[@B10-genes-08-00095],[@B11-genes-08-00095],[@B12-genes-08-00095]\]. Another important mechanistic branch leading to chemoresistance is the dysfunction or loss of p53-mediated apoptotic pathways typically triggered by DNA damage, with examples being dysfunctional activity of the mouse double minute 2 gene (Mdm2) and the p53 encoding gene (TP53) \[[@B13-genes-08-00095],[@B14-genes-08-00095],[@B15-genes-08-00095]\]. In a similar manner, other pro-apoptotic pathways that are typically triggered by cytotoxic drug activities can be hindered within chemoresistant tumour cells. Such pathway issues include cellular FADD-like interleukin 1 beta converting enzyme-inhibitory protein (c-FLIP) and the Bcl-2 protein family members \[[@B16-genes-08-00095],[@B17-genes-08-00095],[@B18-genes-08-00095],[@B19-genes-08-00095]\]. Alternatively, triggering of proliferative/survival signalling pathways such as the ERK and PI3K pathways by means of protein tyrosine kinases, sirtulins, transcription factor kappa B (NFκB) or epidermal growth factor receptor (EGFR) family members can also lead to chemoresistance phenotypes within tumours \[[@B20-genes-08-00095],[@B21-genes-08-00095],[@B22-genes-08-00095]\]. Furthermore, increased efforts by key molecular components of the nucleotide excision repair pathway can take place as a means of limiting tumour cell DNA damage by cytotoxic drug activity \[[@B23-genes-08-00095],[@B24-genes-08-00095],[@B25-genes-08-00095]\]. Other mechanisms directing chemoresistance phenotypes in tumours include drug modulation through inactivation or attenuation of cytotoxic drug activity, modification of drug targets and inhibition of tumour suppressor genes that trigger DNA methylation pathways \[[@B26-genes-08-00095],[@B27-genes-08-00095],[@B28-genes-08-00095]\].

In essence, a particular tumour can be clinically recognized as MDR through the identification of a unique spectrum of dysregulated expression patterns of multiple mRNA biomarkers \[[@B29-genes-08-00095],[@B30-genes-08-00095],[@B31-genes-08-00095],[@B32-genes-08-00095],[@B33-genes-08-00095]\]. However, the discovery of the miRNA and long non-coding RNA (lncRNA) families have created additional layers of genomic regulatory functions \[[@B2-genes-08-00095],[@B34-genes-08-00095],[@B35-genes-08-00095],[@B36-genes-08-00095],[@B37-genes-08-00095],[@B38-genes-08-00095],[@B39-genes-08-00095]\]. Further insight into the roles conducted by miRNAs and lncRNAs in the development of innate and/or acquired chemoresistance properties by tumours is expected to lead to a more accurate depiction of the cancer patient's condition---both at diagnosis and during possible relapse condition.

The sections below represent a comprehensive summary of the global research efforts in delineating the influences and main mechanistic links of such non-coding RNA families on this specific tumour characteristic. Ultimately, the goal of developing novel theranostic measures for employment in the oncology clinic setting can be attained.

3. Influences of miRNAs in Cancer Chemoresistance {#sec3-genes-08-00095}
=================================================

Each physiologically active, individual miRNA consists of a 19--22 nucleotide RNA duplex, bearing a guide strand that is fully or partially complementary to the target transcript to which it binds \[[@B40-genes-08-00095]\]. This binding, which is typically non-totally complementary, leads to either mRNA target cleavage or a hindering effect on the translational phase of protein synthesis by the ribosomal infrastructure. This has the ultimate effect of a reduction in protein level production for the affected target transcript, or effectively post-transcriptional gene regulation \[[@B40-genes-08-00095]\].

Since the discovery of the initial concept of miRNA-driven gene regulation in living organisms at the turn of the millennium, close to 2600 miRNAs have been identified and catalogued in human \[[@B41-genes-08-00095]\]. This large family of gene regulating molecular players leads to a myriad of possibilities to the degree of beneficial and detrimental physiological interactions within the cellular microenvironment, including cancer chemoresistance properties.

[Table 1](#genes-08-00095-t001){ref-type="table"} and [Supplementary Materials Table S1](#app1-genes-08-00095){ref-type="app"} comprise an exhaustive compendium of studies directly focusing on the influence, through dysregulated expression, of specific miRNAs on cancer chemoresistance in the past three years alone:

The list of scientific literature depicting the involvement of miRNAs in cancer chemoresistance, as described above, highlights specific trends that require chemoresistance biomarker investigators to delve further for enhanced insight.

In essence, over 10% of all reported research findings of miRNA influences in cancer chemoresistance demonstrated that such a phenotype modulation was effected through simultaneous dysregulation of multiple miRNAs, rather than an individual putative chemoresistance miRNA---though no specific miRNA combination was identified as most prevalent by the authors \[[@B44-genes-08-00095],[@B46-genes-08-00095],[@B47-genes-08-00095],[@B48-genes-08-00095],[@B49-genes-08-00095],[@B62-genes-08-00095],[@B67-genes-08-00095],[@B71-genes-08-00095],[@B76-genes-08-00095],[@B81-genes-08-00095],[@B85-genes-08-00095],[@B88-genes-08-00095],[@B132-genes-08-00095],[@B133-genes-08-00095],[@B158-genes-08-00095],[@B168-genes-08-00095],[@B201-genes-08-00095],[@B203-genes-08-00095],[@B211-genes-08-00095],[@B212-genes-08-00095],[@B213-genes-08-00095],[@B217-genes-08-00095],[@B223-genes-08-00095],[@B224-genes-08-00095],[@B228-genes-08-00095],[@B230-genes-08-00095]\]. This suggests that miRNA influences on cellular functions also occur at a more complex level, whereby it is a signature dysregulated expression pattern of two (or more) miRNAs that trigger simultaneous downregulation of a specific set of target transcripts leading to an ultimate change in cellular/tissue phenotype. Further evidence for this can be concluded by previous efforts carried out by the authors, whereby a set of seven putative chemoresistance miRNAs were identified for neuroblastoma---a paediatric cancer model \[[@B232-genes-08-00095]\].

The mechanistic links between miRNA activity and chemoresistance development that have been identified so far reveal that miRNA dysregulated expression can indeed influence the main cellular pathways (described in [Section 2](#sec2-genes-08-00095){ref-type="sec"} above) that are directly affecting chemoresistance emergence in tumour models.

In the first instance, miRNAs have been recognized to regulate MDR-related molecular players such as multidrug resistance-associated protein 1 (MRP-1) \[[@B66-genes-08-00095]\]. The study carried out by Gao and colleagues identified the gene regulatory effects of miR-145-5p on MRP-1, ultimately enhancing the level of chemosensitivity in the doxorubicin resistant MCF-7 breast cancer cell line \[[@B66-genes-08-00095]\]. Furthermore, the study performed by Zhan and colleagues identified that MRP-1 could also be downregulated through the overexpression of miR-145-5p in cisplatin-resistant gallbladder tumour models, resulting in sensitizing of the tumour cells to cisplatin activity \[[@B99-genes-08-00095]\]. Similarly, the study conducted by Zhao and colleagues revealed that a combination of four miRNAs, namely miR-302a-3p/b-3p/c-3p/d-3p, concomitantly provide similar effects in doxorubicin-resistant breast cancer MCF-7 cell lines \[[@B71-genes-08-00095]\]. This study confirmed through RT-qPCR and Western blotting techniques that over-expression of these miRNAs induced sensitization to doxorubicin through a reduction in the expression level of MAP/ERK kinase 1 (MEKK1), leading to an overall downregulation of P-glycoprotein (P-gp) expression \[[@B71-genes-08-00095]\].

Other studies have demonstrated miRNA influences on the p53 pathway status as a means of inducing chemoresistance properties. The study conducted by Shen and colleagues recognized the effect of up-regulated miR-29a-3p in exacerbating doxorubicin-resistance in breast cancer cell lines, through its regulatory function on PTEN and GSK3β, that are two major components of the PTEN/AKT/GSK3β signalling pathway providing feedback to TP53 \[[@B55-genes-08-00095]\]. Further evidence for such miRNA influences on p53 modulation include the study carried out by Qin and colleagues, who revealed that the over-expression of miR-182-5p can induce cisplatin chemoresistance in hepatocellular carcinoma HepG2-Rcells \[[@B130-genes-08-00095]\]. This exacerbation was found to occur through the direct regulatory effect of the miRNA on tumour protein 53-induced nuclear protein 1 (TP53INP1) \[[@B130-genes-08-00095]\].

Evidence for the mechanistic link between miRNA activity and apoptotic pathway dysfunction for the emergence of chemoresistance in cancer includes the study performed by Zhang and colleagues \[[@B89-genes-08-00095]\]. The outcome of this investigation identified the exacerbating effect of miR-425-5p on chemoresistance in colorectal cancer HCT116 cell lines as well as in xenograft models, through direct action on programmed cell death 10 (PCD10) \[[@B89-genes-08-00095]\]. In addition, Stojcheva and colleagues reported the acquisition of chemoresistance properties by glioblastoma to alkylators such as temozolomide due to miR-138-5p direct regulatory function on BIM, which is a Bcl-2 interacting mediator of apoptosis \[[@B111-genes-08-00095]\]. Furthermore, miR-182-5p was also identified as playing a key role in the development of chemoresistance in ovarian carcinomas due to its gene-regulating capacity on programmed cell death 4 (PDCD4) \[[@B214-genes-08-00095]\].

The influences of miRNA activity on cell proliferative function, as another mechanism for chemoresistance emergence, is described through the study performed by Ye and colleagues on chemoresistant breast cancer cell line models \[[@B59-genes-08-00095]\]. This seminal investigation recognized the downregulatory effect of miR-484 on cytidine deaminase (CDA), which is a major molecular player in controlling cell proliferation through its suppressive function on cyclin E-CDK2 signalling, thereby inhibiting any cell-cycle progress \[[@B59-genes-08-00095]\]. Interestingly, the investigation conducted by Phatak and colleagues on oesophageal squamous cancer cell line models revealed that overexpression of miR-214-3p resulted in the sensitization of such tissue cultures to cisplatin \[[@B171-genes-08-00095]\]. Such a reduction in chemoresistance by miR-214-3p was mediated by direct regulation of surviving expression, together with indirect regulation by means of downregulation of CUG-BP1, leading to decreased mRNA stability in the targeted tumour cells \[[@B171-genes-08-00095]\].

Cytotoxic drug-induced DNA damage response pathway was also found to be affected by miRNA influence. The study performed by Li and colleagues identified that such a pathway can be activated by upregulation of the inhibitor of growth 5 (ING5) gene, which is in turn regulated by miR-193a-3p within the bladder cancer cell line 5637 \[[@B49-genes-08-00095]\]. In addition, inhibition of ING5 in this study resulted in a drastic reduction of the DNA damage response pathway within the same cell line \[[@B49-genes-08-00095]\].

Evidence for the modulation of cytotoxic drug targets by miRNAs can be reflected in the study performed by Liang and colleagues on gemcitabine resistant MiaPiaCa-2 pancreatic cell cancer models \[[@B216-genes-08-00095]\]. Results of this study led to the regulatory role of miR-33a in β-catenin downregulation, with the latter being a key molecular player in directing the expression levels of multiple genes including cyclin D1, surviving and MDR-1 \[[@B216-genes-08-00095]\].

In addition to the effect of multiple miRNAs on cancer chemoresistance, several studies reported the possible influences exhibited by circulating miRNAs (in blood), typically through extracellular vesicle or exosome transport \[[@B67-genes-08-00095],[@B168-genes-08-00095],[@B172-genes-08-00095],[@B205-genes-08-00095],[@B228-genes-08-00095]\].

Exosomes can be characterized as endocytic vesicles that can be secreted by multiple cell types within the human body, carrying a spectrum of molecular players, including miRNAs, for the purpose of cell-cell communication (e.g., antigen presentation) \[[@B233-genes-08-00095]\]. The transfer of genomic components such as mRNA and miRNAs between two individual cells of varying morphology, such as from bone marrow to mast cells, was also identified to lead to novel protein synthesis within the recipient cells \[[@B233-genes-08-00095]\]. Consequently, exosomal transfer can be reliably considered as an additional method of influence on multiple molecular pathways, since the desired physiological effect/s is induced from cellular populations situation within remote locations.

The effect of exosome activity can also be linked within the context of cancer chemoresistance, such as the findings described by Chen and colleagues \[[@B67-genes-08-00095]\]. This study highlighted the effect of exosomes on chemoresistant breast cancer cell lines, focusing on the transfer of miR-222-3p from doxorubicin resistant MCF-7 cell line to a chemosensitive MCF-7 cell line model \[[@B67-genes-08-00095]\]. This exosomal transfer ultimately rendered the recipient breast carcinoma cell line more resistant to doxorubicin activity following post-transfer functional assays \[[@B67-genes-08-00095]\].

Furthermore, the study carried out by Au Yeung and colleagues identified and validated the effect of exosomal transfer of miRNAs in drug resistant ovarian cancer models \[[@B205-genes-08-00095]\]. This study identified the exosomal transfer of miR-21-5p from cancer-associated adipocytes (within the omental stroma) into ovarian carcinoma cell populations \[[@B205-genes-08-00095]\]. This transfer ultimately conferred paclitaxel chemoresistance properties to the recipient ovarian carcinoma cells due to the direct regulatory effect of miR-21-5p on the transcript for apoptotic protease activating factor 1 (APAF1) \[[@B205-genes-08-00095]\].

Exosome transfer was also identified as being implicated in chemoresistance conferring to prostate cancer, as highlighted by the investigation by Li and colleagues \[[@B228-genes-08-00095]\]. The study identified 29 dysregulated miRNAs within exosomes derived from two paclitaxel resistant prostate cancer cell line models \[[@B228-genes-08-00095]\].

4. Influences of lncRNAs in Cancer Chemoresistance {#sec4-genes-08-00095}
==================================================

Notwithstanding the myriad of networking interactions leading to miRNA directed gene regulatory effects within cellular populations, the more recent discovery of a separate family of non-coding RNAs, namely lncRNAs, leads to the identification of an additional level of gene regulation within the human body. According to the latest version of LNCipedia, there are over 60,000 members of the lncRNA family that have been catalogued \[[@B234-genes-08-00095],[@B235-genes-08-00095]\]. LncRNAs are non-coding RNA genes of at least 200 nucleotides long. LncRNAs can either act as positive or negative regulators of target gene expression, with this activity being directed either on transcripts originating from the same locus as the lncRNA itself (cis-acting) or directed on target transcripts originating on other loci (trans-acting) \[[@B6-genes-08-00095]\].

[Table 2](#genes-08-00095-t002){ref-type="table"} and [Supplementary Materials Table S2](#app1-genes-08-00095){ref-type="app"} highlight in detail the currently reported scientific evidence for the influence of multiple lncRNAs on varying cancer models. Interestingly, previous studies have highlighted the detrimental effects of one individual lncRNA, known as homeobox transcript antisense RNA (HOTAIR), having an elevated prevalence within multiple tumour chemoresistance phenotypes \[[@B236-genes-08-00095],[@B237-genes-08-00095],[@B238-genes-08-00095]\].

The investigation carried out by Fang and colleagues focused on the possible effects of HOTAIR on chemoresistance in small cell lung cancer, mainly through knock-down of the lncRNA in chemoresistant and parental cell line models, followed by viability assays \[[@B236-genes-08-00095]\]. Apart from confirming HOTAIR knock-down with enhanced chemosensitivity of the affected cell lines to doxorubicin, cisplatin and etoposide, the study also recognized the chemoresistance phenotype was additionally linked to increased methylation of homeobox A1 (HOXA1), suggesting HOTAIR influences in affecting such a methylation status \[[@B236-genes-08-00095]\]. The study also confirmed that HOTAIR inhibition, through short hairpin RNA antagonist employment in murine tumour xenograft models for small cell lung cancer, led to a reduction in tumour growth \[[@B236-genes-08-00095]\].

In a similar study conducted by Liu and colleagues, HOTAIR expression was discovered to be up-regulated in the cisplatin-resistant A549 lung adenocarcinoma cell line model, with consequent re-sensitisation of the cell line to cisplatin exposure following HOTAIR knock-down \[[@B237-genes-08-00095]\]. This short interfering RNA (siRNA)-induced HOTAIR knock-down effect was also linked to enhanced cell cycle arrest and apoptosis, together with a reduction in cell proliferation, through control of p21^WAF1/CIP1^ expression \[[@B237-genes-08-00095]\].

Furthermore, the study performed by Ozes and colleagues investigated the possible influences of HOTAIR on ovarian cancer chemoresistance properties, specifically for platinum-based chemotherapeutic agent chemoresistance \[[@B238-genes-08-00095]\]. The results of the study highlighted exacerbated HOTAIR expression within platinum drug resistant ovarian tumour samples when compared to primary ovarian tumour counterpart samples \[[@B238-genes-08-00095]\]. The study also revealed that HOTAIR up-regulation allows for prolonged NF-*K*B expression, leading to extended DNA damage response mechanisms to take place, following platinum-based drug exposure and therefore contributing to the chemoresistance phenotype development \[[@B238-genes-08-00095]\].

In addition to HOTAIR, another putative chemoresistance lncRNA of particular interest is MRUL (NR_024549), since the chromosomal locus for MRUL is in close proximity to the locus for the Multi Drug Resistance 1 (MDR1) gene---the latter being recognised as the most important gene to induce cancer chemoresistance phenotypes \[[@B239-genes-08-00095]\]. Such a study highlights the unique properties of lncRNAs in their capacity to perform cis-regulatory functions on neighbouring transcripts of clinical relevance.

Evidence for the regulatory role of lncRNAs in directing both cell proliferative signalling and drug modulation mechanisms affecting chemoresistance can be found in the study performed by Dong and colleagues \[[@B240-genes-08-00095]\]. This particular study recognised the effect of GAS5 in enhancing apoptosis due to gefitinib activity within innate EGFR tyrosine-kinase inhibitor (TKI) resistant lung adenocarcinomas (A549 cell line), through the gene regulating role of GAS5 on insulin-like growth factor 1 receptor (IGF-1R) \[[@B240-genes-08-00095]\]. Interestingly, the investigation conducted by Cheng and colleagues identified UCA1 as being upregulated in acquired (non T790M) EGFR-TKI resistant non-small cell lung cancer \[[@B241-genes-08-00095]\]. UCA1 knockdown assays confirmed that this lncRNA, when downregulated, allowed for increased gefitinib sensitivity and furthermore inhibited AKT/mTOR functions \[[@B241-genes-08-00095]\].

5. Conclusions and Perspectives {#sec5-genes-08-00095}
===============================

In essence, it can be stated that ncRNAs do have a place in regulating cancer chemoresistance properties, merely based on the body of evidence described above. Furthermore, the recent scientific literature on this niche research reveals that both miRNAs and lncRNAs have important roles in affecting the main mechanisms currently known to lead to the development of cancer chemoresistance phenotypes (see [Figure 1](#genes-08-00095-f001){ref-type="fig"}).

Undoubtedly, the recent progress in molecular analytical and sequencing technologies has advanced to the levels that the entire miRnome/lncRNome can be quantified in a rapid and reliable manner, facilitating investigators' efforts to identify unique expression profiles that are linked with defined tumour chemoresistance properties.

Such breakthroughs in technology are proving to be essential for biomarker researchers since evermore studies are leading to the paradigm that tumour clinical characteristics such as chemoresistance are the result of influence by multiple miRNAs and/or lncRNAs acting in a simultaneous manner, and not merely the outcome of one individual non-coding RNA's dysregulated expression. The issue with this paradigm is the degree of complexity and resource consumption in carrying out detailed functional analyses to validate each permutation of non-coding RNA influences from an identified expression profile comprising just a handful of miRNAs/lncRNAs. Hopefully, further advances in bioinformatics and analytical technologies can permit more accurate trawling efforts to pinpoint such biomarkers and/or possibly allow for high throughput functional analyses for the entire miRnome/lncRNome in a rapid and effective manner.

The clinical importance for all global research efforts to identify and validate novel non-coding RNA biomarkers for cancer chemoresistance must certainly not be underestimated. The validation of reliable miRNA and/or lncRNA biomarkers for individual cancer chemoresistance (be it innate or acquired) can lead to the exploitation of such biomarkers as novel drug targets. Ultimately, antagonists and/or mimics (depending whether the miRNA/lncRNA is up- or down-regulated) for each non-coding RNA drug target can be developed and safely delivered as adjunct therapy together with conventional chemotherapeutic drugs. The adjuvant therapy leads to enhanced tumour sensitivity for the conventional chemotherapeutic drugs, therefore markedly enhancing chemotherapy effectiveness.

Alternatively, in patients who are particularly prone to the dose limiting adverse effects of conventional chemotherapy, the doses for the latter can be reduced due to the addition of the novel non-coding RNA-directed therapy. This leads to a great reduction in dose-limiting adverse effects and consequent discomfort in the cancer patient.

Finally, such chemoresistance biomarker expression profiles can be easily quantified from tumour biopsy through real time quantitative polymerase chain reaction (RT-qPCR) assays. The additional clinical information regarding the chemoresistance properties can provide the oncologist with valuable pre-emptive knowledge. Such additional information aids in developing a bespoke chemotherapy drug combination for the cancer patient that maximizes therapeutic efficacy and therefore minimises "trial and error" chemotherapy regimes, since the tumour would be exposed only to the chemotherapeutic agents to which it is fully sensitive.

However, efforts to render such a powerful theranostic technology is confronted with two main issues for it to become commonplace within global reach.

Firstly, the most effective technologies for accurate quantitative analysis of ncRNAs remain to be real-time, reverse transcription quantitative PCR (RT-qPCR) and next-generation sequencing. Both such technologies require sophisticated equipment and highly skilled staff dedicated to the processing of clinical samples for miRNA and lncRNA expression profiling. Eventually, these technologies can be miniaturized and simplified to the level of the development of a cost-effective point-of-care diagnostic apparatus that can be utilised by healthcare professionals with limited experience in the analytical technologies being employed.

Secondly, the issues regarding safe and effective drug delivery of novel miRNA and lncRNA therapeutics still pose a hurdle to rapid development of such translational medicine and effective availability for use by the individual cancer patient. Notwithstanding this issue however, the pharmaceutical industry are currently focusing hard on multiple circumvention methods for effectively providing efficient drug delivery options. These efforts are concentrated in pharmaceutical companies that are entirely dedicated to the research and development of miRNA and lncRNA-based therapeutics.

However, the authors sincerely believe that, despite such challenges, the advent of such novel clinical oncology drug treatment/management protocols will become a reality within the hospital setting in the not too distant future.

The following are available online at [www.mdpi.com/2073-4425/8/3/95/s1](www.mdpi.com/2073-4425/8/3/95/s1), Table S1: Frequency chart depicting prevalence of individual miRNAs in specific cancer models reported in the literature (as depicted in [Table 1](#genes-08-00095-t001){ref-type="table"} above) and from the data reported in the review article by Garofalo and Croce \[[@B42-genes-08-00095]\], Table S2: Frequency chart depicting prevalence of individual lncRNAs in specific cancer models reported in the literature (as depicted in [Table 2](#genes-08-00095-t002){ref-type="table"} above).

###### 

Click here for additional data file.
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genes-08-00095-t001_Table 1

###### 

Compendium of miRNAs identified to influence cancer chemoresistance since 2013, either as oncomiRs or as tumour suppressors. A details list of additional such miRNAs, identified prior to 2013, can be obtained through the open-access review publication by Garofalo and Croce \[[@B42-genes-08-00095]\]. Furthermore, due to recent changes in miRNA annotation and nomenclature, the putative miRNAs mentioned in the literature have been listed according to the latest annotation changes on the miRBase repository, using the miRBase tracker webtool (annotation history of mature miRNA searches) \[[@B43-genes-08-00095]\]. Table keys: u, Upregulated; d, Downregulated; nd, not described; +, Increase; −, Reduction.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miRNA/s Involved (Species---*Homo sapiens*)   Accession (MIMAT) Number         Cancer Model                  Affected Chemotherapeutic Drugs                           Dysregulation Status   Effect on Chemo-Resistance Phenotype   Ref.
  --------------------------------------------- -------------------------------- ----------------------------- --------------------------------------------------------- ---------------------- -------------------------------------- -----------------------------------------------------------------------
  miR-34a-5p                                    0000255                          bladder                       neoadjuvant chemotherapy                                  nd                     \+                                     \[[@B44-genes-08-00095]\]

  miR-100-5p                                    0000098                                                                                                                                                                                

  miR-146b-5p                                   0002809                                                                                                                                                                                

  miR-9-5p                                      0000441                                                                                                                                                                                

  miR-193a-3p                                   0000459                                                                                                                                                                                

  let-7c-5p                                     0000064                          bladder                       Platinum-based neoadjuvant chemotherapy                   d                      \+                                     \[[@B45-genes-08-00095]\]

  miR-1290                                      0005880                          bladder                       gemcitabine                                               u                      \+                                     \[[@B46-genes-08-00095]\]

  miR-138-5p                                    0000430                          u                             \+                                                                                                                      

  let-7i-5p                                     0000415                          d                             \+                                                                                                                      

  let-7b-5p                                     0000063                          d                             \+                                                                                                                      

  miR-193a-3p                                   0000459                          bladder                       MDR                                                       u                      \+                                     \[[@B47-genes-08-00095],[@B48-genes-08-00095],[@B49-genes-08-00095]\]

  miR-21-5p                                     0000076                          breast                        gemcitabine                                               u                      \+                                     \[[@B50-genes-08-00095]\]

  miR-25-3p                                     0000081                          breast                                                                                  d                      −                                      \[[@B51-genes-08-00095]\]

  miR-125b-5p                                   0000423                          breast                                                                                  u                      \+                                     \[[@B52-genes-08-00095]\]

  miR-149-5p                                    0000450                          breast                                                                                  d                      \+                                     \[[@B53-genes-08-00095]\]

  miR-320a                                      0000510                          breast                                                                                  d                      \+                                     \[[@B54-genes-08-00095]\]

  miR-29a-3p                                    0000086                          breast                        doxorubicin                                               u                      \+                                     \[[@B55-genes-08-00095]\]

  miR-129-2-3p                                  0004605                          breast                        docetaxel                                                 u                      \+                                     \[[@B56-genes-08-00095]\]

  miR-139-5p                                    0000250                          breast                        docetaxel                                                 d                      \+                                     \[[@B57-genes-08-00095]\]

  miR-760                                       0004957                          breast                        doxorubicin                                               u                      \+                                     \[[@B58-genes-08-00095]\]

  miR-484                                       0002174                          breast                                                                                  u                      \+                                     \[[@B59-genes-08-00095]\]

  miR-223-3p                                    0000280                          breast                                                                                  d                      \+                                     \[[@B60-genes-08-00095]\]

  miR-489-3p                                    0002805                          breast                                                                                  u                      \-                                     \[[@B61-genes-08-00095]\]

  miR-34a-5p                                    0000255                          breast                        doxorubicin\                                              u                      −                                      \[[@B62-genes-08-00095]\]
                                                                                                               docetaxel                                                                                                               

  miR-222-3p                                    0000279                          d                             −                                                                                                                       

  miR-452-5p                                    0001635                          d                             −                                                                                                                       

  miR-29a-3p                                    0000086                          d                             −                                                                                                                       

  let-7a-5p                                     0000062                          breast                        epirubicin                                                d                      \+                                     \[[@B63-genes-08-00095]\]

  miR-181b-5p                                   0000257                          breast                        doxorubicin                                               u                      \+                                     \[[@B64-genes-08-00095]\]

  miR-141-3p                                    0000432                          breast                        docetaxel                                                 u                      \+                                     \[[@B65-genes-08-00095]\]

  miR-145-5p                                    0000437                          breast                        doxorubicin                                               u                      −                                      \[[@B66-genes-08-00095]\]

  miR-100-5p                                    0000098                          breast                        doxorubicin\                                              u                      \+                                     \[[@B67-genes-08-00095]\]
                                                                                                               docetaxel                                                                                                               

  miR-222-3p                                    0000279                          u                             \+                                                                                                                      

  miR-30a-3p                                    0000088                          u                             \+                                                                                                                      

  miR-30a-5p                                    0000087                          u                             \+                                                                                                                      

  miR-30c-5p                                    0000244                          breast                                                                                  u                      −                                      \[[@B68-genes-08-00095]\]

  miR-155-5p                                    0000646                          breast                        tamoxifen                                                 u                      \+                                     \[[@B69-genes-08-00095]\]

  miR-663a                                      0003326                          breast                        doxorubicin                                               u                      \+                                     \[[@B70-genes-08-00095]\]

  miR-302a-3p                                   0000684                          breast                        doxorubicin                                               u                      −                                      \[[@B71-genes-08-00095]\]

  miR-302b-3p                                   0000715                          u                             −                                                                                                                       

  miR-302c-3p                                   0000717                          u                             −                                                                                                                       

  miR-302d-3p                                   0000718                          u                             −                                                                                                                       

  miR-200c-3p                                   0000617                          breast                        doxorubicin                                               u                      −                                      \[[@B72-genes-08-00095]\]

  miR-181a-5p                                   0000256                          cervical                      cisplatin                                                 u                      \+                                     \[[@B73-genes-08-00095]\]

  miR-125a-5p                                   0000443                          cervical                      paclitaxel                                                u                      −                                      \[[@B74-genes-08-00095]\]

  miR-100-5p                                    0000098                          chondrosarcoma                cisplatin                                                 u                      −                                      \[[@B75-genes-08-00095]\]

  miR-4299                                      0016851                          colon                         capecitabine\                                             d                      −                                      \[[@B76-genes-08-00095]\]
                                                                                                               oxaliplatin                                                                                                             

  miR-196b-5p                                   0001080                          u                             −                                                                                                                       

  miR-34a-5p                                    0000255                          colon                         5-fluorouracil                                            u                      −                                      \[[@B77-genes-08-00095]\]

  miR-122-5p                                    0000421                          colon                         5-fluorouracil                                            u                      −                                      \[[@B78-genes-08-00095]\]

  miR-409-3p                                    0001639                          colon                         oxaliplatin                                               u                      −                                      \[[@B79-genes-08-00095]\]

  miR-223-3p                                    0000280                          colon                                                                                   d                      \+                                     \[[@B60-genes-08-00095]\]

  miR-494-3p                                    0002816                          colon                         5-fluorouracil                                            u                      −                                      \[[@B80-genes-08-00095]\]

  miR-125a-5p                                   0000443                          colon                         paclitaxel                                                u                      −                                      \[[@B81-genes-08-00095]\]

  miR-125b-5p                                   0000423                                                                                                                                                                                

  miR-218-5p                                    0000275                          colorectal                    5-fluorouracil                                            u                      −                                      \[[@B82-genes-08-00095]\]

  miR-203a-3p                                   0000264                          colorectal                    paclitaxel\                                               u                      −                                      \[[@B83-genes-08-00095],[@B84-genes-08-00095]\]
                                                                                                               5-fluorouracil                                                                                                          

  miR-1914-3p                                   0007890                          colorectal                    capecitabine\                                             u                      −                                      \[[@B85-genes-08-00095]\]
                                                                                                               oxaliplatin                                                                                                             

  miR-1915-3p                                   0007892                          u                             −                                                                                                                       

  miR-204-5p                                    0000265                          colorectal                    5-fluorouracil                                            u                      −                                      \[[@B86-genes-08-00095]\]

  miR-139-5p                                    0000250                          colorectal                    5-fluorouracil                                            u                      −                                      \[[@B87-genes-08-00095]\]

  miR-205-5p                                    0000266                          colorectal                                                                              u                      \+                                     \[[@B88-genes-08-00095]\]

  miR-373-3p                                    0000726                          u                             \+                                                                                                                      

  miR-425-5p                                    0003393                          colorectal                    5-fluorouracil\                                           u                      \+                                     \[[@B89-genes-08-00095]\]
                                                                                                               oxaliplatin                                                                                                             

  miR-429                                       0001536                          colorectal                    5-fluorouracil                                            u                      \+                                     \[[@B90-genes-08-00095]\]

  miR-34a-5p                                    0000255                          colorectal                    5-fluorouracil                                            u                      −                                      \[[@B91-genes-08-00095]\]

  miR-519c-3p                                   0002832                          colorectal                    5-fluorouracil\                                           d                      \+                                     \[[@B92-genes-08-00095]\]
                                                                                                               irinotecan                                                                                                              

  miR-520g-3p                                   0002858                          colorectal                    5-fluorouracil                                            u                      \+                                     \[[@B93-genes-08-00095]\]

  miR-23a-3p                                    0000078                          colorectal                    5-fluorouracil                                            u                      \+                                     \[[@B94-genes-08-00095]\]

  miR-96-5p                                     0000095                          colorectal                    5-fluorouracil                                            u                      −                                      \[[@B95-genes-08-00095]\]

  miR-587                                       0003253                          colorectal                    5-fluorouracil                                            u                      \+                                     \[[@B96-genes-08-00095]\]

  miR-218-5p                                    0000275                          endometrial                   paclitaxel                                                u                      −                                      \[[@B97-genes-08-00095]\]

  miR-125b-5p                                   0000423                          ewing sarcoma                 doxorubicin                                               u                      \+                                     \[[@B98-genes-08-00095]\]

  miR-145-5p                                    0000437                          gallbladder                   cisplatin                                                 u                      −                                      \[[@B99-genes-08-00095]\]

  miR-1284                                      0005941                          gastric                       vincristine                                               u                      −                                      \[[@B100-genes-08-00095]\]

  miR-375                                       0000728                          gastric                       cisplatin                                                 u                      −                                      \[[@B101-genes-08-00095]\]

  miR-23b-3p                                    0000418                          gastric                       MDR                                                       u                      −                                      \[[@B102-genes-08-00095]\]

  miR-20a-5p                                    0000075                          gastric                       cisplatin                                                 u                      \+                                     \[[@B103-genes-08-00095]\]

  miR-34c-5p                                    0000686                          gastric                       paclitaxel                                                d                      \+                                     \[[@B104-genes-08-00095]\]

  miR-16-5p                                     0000069                          gastric                       etoposide\                                                u                      −                                      \[[@B105-genes-08-00095]\]
                                                                                                               5-fluorouracil                                                                                                          

  miR-9-5p                                      0000441                          glioblastoma                  temozolomide                                              u                      \+                                     \[[@B106-genes-08-00095]\]

  miR-20a-5p                                    0000075                          glioblastoma                  temozolomide                                              u                      −                                      \[[@B107-genes-08-00095]\]

  miR-21-5p                                     0000076                          glioblastoma                  doxorubicin                                               u                      \+                                     \[[@B108-genes-08-00095]\]

  miR-873-5p                                    0004953                          glioblastoma                  cisplatin                                                 u                      −                                      \[[@B109-genes-08-00095]\]

  miR-210-3p                                    0000267                          glioblastoma                  temozolomide                                              u                      −                                      \[[@B110-genes-08-00095]\]

  miR-138-5p                                    0000430                          glioblastoma                  temozolomide                                              u                      \+                                     \[[@B111-genes-08-00095]\]

  miR-125b-5p                                   0000423                          glioblastoma                  temozolomide                                              u                      −                                      \[[@B112-genes-08-00095]\]

  miR-203a-3p                                   0000264                          glioblastoma                                                                            d                      \+                                     \[[@B113-genes-08-00095]\]

  let-7b-5p                                     0000063                          glioblastoma                  cisplatin                                                 d                      \+                                     \[[@B114-genes-08-00095]\]

  miR-181b-5p                                   0000257                          glioma                        temozolomide                                              u                      −                                      \[[@B115-genes-08-00095]\]

  miR-124-3p                                    0000422                          glioma                        temozolomide                                              u                      −                                      \[[@B116-genes-08-00095]\]

  miR-200a-3p                                   0000682                          glioma                        temozolomide                                              u                      −                                      \[[@B117-genes-08-00095]\]

  miR-136-5p                                    0000448                          glioma                        cisplatin                                                 u                      −                                      \[[@B118-genes-08-00095]\]

  miR-10b-5p                                    0000254                          head/neck squamous cell       cisplatin                                                 u                      \+                                     \[[@B119-genes-08-00095]\]

  miR-21-5p                                     0000076                          hepatocellular                                                                          u                      \+                                     \[[@B120-genes-08-00095]\]

  miR-34a-5p                                    0000255                          hepatocellular                sorafenib                                                 u                      −                                      \[[@B121-genes-08-00095]\]

  miR-26b-5p                                    0000083                          hepatocellular                doxorubicin                                               u                      −                                      \[[@B122-genes-08-00095]\]

  miR-106a-5p                                   0000103                          hepatocellular                gemcitabine                                               d                      \+                                     \[[@B123-genes-08-00095]\]

  miR-101-3p                                    0000099                          hepatocellular                cisplatin                                                 u                      −                                      \[[@B124-genes-08-00095]\]

  miR-125b-5p                                   0000423                          hepatocellular                5-fluorouracil                                            u                      −                                      \[[@B125-genes-08-00095]\]

  miR-145-5p                                    0000437                          hepatocellular                doxorubicin                                               u                      −                                      \[[@B126-genes-08-00095]\]

  miR-141-3p                                    0000432                          hepatocellular                5-fluorouracil                                            u                      \+                                     \[[@B127-genes-08-00095]\]

  miR-122-5p                                    0000421                          hepatocellular                sorafenib                                                 d                      \+                                     \[[@B128-genes-08-00095]\]

  miR-340-5p                                    0004692                          hepatocellular                cisplatin                                                 u                      −                                      \[[@B129-genes-08-00095]\]

  miR-182-5p                                    0000259                          hepatocellular                cisplatin                                                 u                      \+                                     \[[@B130-genes-08-00095]\]

  miR-215-5p                                    0000272                          hepatocellular                doxorubicin                                               u                      \+                                     \[[@B131-genes-08-00095]\]

  miR-135b-5p                                   0000758                          leukaemia                     genotoxic agent treatment (eg., etoposide, doxorubicin)   u                      \+                                     \[[@B132-genes-08-00095]\]

  miR-196b-5p                                   0001080                          u                             \+                                                                                                                      

  miR-17-3p                                     0000071                          leukaemia                                                                               d                      −                                      \[[@B133-genes-08-00095]\]

  miR-17-5p                                     0000070                          d                             −                                                                                                                       

  miR-20a-5p                                    0000075                          d                             −                                                                                                                       

  miR-21-5p                                     0000076                          leukaemia                     etoposide, doxorubicin                                    d                      −                                      \[[@B134-genes-08-00095]\]

  miR-181a-5p                                   0000256                          leukaemia                     doxorubicin                                               u                      \+                                     \[[@B135-genes-08-00095]\]

  miR-181c-5p                                   0000258                          leukaemia                     chronic myelocytic leukaemia                              u                      −                                      \[[@B136-genes-08-00095]\]

  let-7a-5p                                     0000062                          leukaemia                     cytarabine                                                d                      \+                                     \[[@B137-genes-08-00095]\]

  let-7c-5p                                     0000064                          lung                          cisplatin                                                 u                      −                                      \[[@B138-genes-08-00095]\]

  miR-1244                                      0005896                          lung                          cisplatin                                                 u                      −                                      \[[@B139-genes-08-00095]\]

  miR-96-5p                                     0000095                          lung                          cisplatin                                                 u                      \+                                     \[[@B140-genes-08-00095]\]

  miR-107                                       0000104                          lung                          cisplatin                                                 u                      −                                      \[[@B141-genes-08-00095]\]

  miR-378a-3p                                   0000732                          lung                          cisplatin                                                 u                      −                                      \[[@B142-genes-08-00095]\]

  miR-192-5p                                    0000222                          lung                          cisplatin                                                 u                      \+                                     \[[@B143-genes-08-00095]\]

  miR-205-5p                                    0000266                          lung                                                                                    u                      \+                                     \[[@B144-genes-08-00095]\]

  miR-21-5p                                     0000076                          lung                          cisplatin                                                 d                      −                                      \[[@B145-genes-08-00095]\]

  miR-24-3p                                     0000080                          lung                          etoposide, cisplatin                                      d                      \+                                     \[[@B146-genes-08-00095]\]

  miR-299-3p                                    0000687                          lung                          doxorubicin                                               u                      −                                      \[[@B147-genes-08-00095]\]

  miR-27a-3p                                    0000084                          lung                          cisplatin                                                 u                      −                                      \[[@B148-genes-08-00095]\]

  miR-551a                                      0003214                          lung                                                                                    u                      \+                                     \[[@B149-genes-08-00095]\]

  miR-100-5p                                    0000098                          lung                                                                                    u                      \+                                     \[[@B150-genes-08-00095]\]

  miR-146a-5p                                   0000449                          lung                          cisplatin                                                 u                      \+                                     \[[@B151-genes-08-00095]\]

  miR-182                                       (sequence not listed in paper)   lung                          cisplatin                                                 u                      \+                                     \[[@B152-genes-08-00095]\]

  miR-650                                       0003320                          lung                          docetaxel                                                 u                      \+                                     \[[@B153-genes-08-00095]\]

  miR-224-5p                                    0000281                          lung                          cisplatin                                                 u                      \+                                     \[[@B154-genes-08-00095]\]

  miR-451a                                      0001631                          lung                          docetaxel                                                 u                      −                                      \[[@B155-genes-08-00095]\]

  miR-15b-5p                                    0000417                          lung                          cisplatin                                                 u                      −                                      \[[@B156-genes-08-00095]\]

  miR-148b-3p                                   0000759                          lung                          cisplatin                                                 u                      −                                      \[[@B157-genes-08-00095]\]

  miR-205-5p                                    0000266                          lung                          carboplatin                                               u                      \+                                     \[[@B158-genes-08-00095]\]

  miR-218-5p                                    0000275                          u                             \+                                                                                                                      

  miR-26b-5p                                    0000083                          lung                                                                                    d                      −                                      \[[@B159-genes-08-00095]\]

  miR-192-5p                                    0000222                          lung                          gemcitabine, cisplatin                                    u                      −                                      \[[@B160-genes-08-00095]\]

  miR-197-3p                                    0000227                          lung                          platinum-based                                            d                      \+                                     \[[@B161-genes-08-00095]\]

  miR-7-5p                                      0000252                          lung                                                                                    u                      −                                      \[[@B162-genes-08-00095]\]

  miR-940                                       0004983                          lung                          cisplatin                                                 d                      \+                                     \[[@B163-genes-08-00095]\]

  miR-200b-3p                                   0000318                          lung                          docetaxel                                                 u                      −                                      \[[@B164-genes-08-00095]\]

  miR-200c-3p                                   0000617                          lung                          methotrexate                                              u                      −                                      \[[@B165-genes-08-00095]\]

  miR-494-3p                                    0002816                          lung                                                                                    u                      −                                      \[[@B166-genes-08-00095]\]

  miR-377-3p                                    0000730                          lymphoma\                     venetoclax                                                u                      \+                                     \[[@B167-genes-08-00095]\]
                                                                                 (b-cell)                                                                                                                                              

  miR-125b-5p                                   0000423                          lymphoma\                     cyclophosphamide, doxorubicin, vincristine                u                      \+                                     \[[@B168-genes-08-00095]\]
                                                                                 (b-cell)                                                                                                                                              

  miR-130a-3p                                   0000425                          u                             \+                                                                                                                      

  miR-21-5p                                     0000076                          nasopharyngeal                cisplatin                                                 u                      \+                                     \[[@B169-genes-08-00095]\]

  miR-634                                       0003304                          nasopharyngeal                paclitaxel                                                u                      −                                      \[[@B170-genes-08-00095]\]

  miR-214-3p                                    0000271                          oesophageal (squamous cell)   cisplatin                                                 u                      −                                      \[[@B171-genes-08-00095]\]

  miR-21-5p                                     0000076                          oesophageal (squamous cell)   5-fluorouracil\                                           u                      \+                                     \[[@B172-genes-08-00095]\]
                                                                                                               cisplatin\                                                                                                              
                                                                                                               (circulating miRnas)                                                                                                    

  miR-193a-3p                                   0000459                          oesophageal                   chemoradiation                                            u                      −                                      \[[@B173-genes-08-00095]\]

  miR-27a-3p                                    0000084                          oesophageal                   cisplatin                                                 u                      \+                                     \[[@B174-genes-08-00095]\]

  miR-221-3p                                    0000278                          oesophageal                   5-fluorouracil                                            u                      \+                                     \[[@B175-genes-08-00095]\]

  miR-181a-5p                                   0000256                          oral squamous cell            cisplatin                                                 u                      −                                      \[[@B176-genes-08-00095]\]

  miR-23a-3p                                    0000078                          oral squamous cell            cisplatin                                                 u                      \+                                     \[[@B177-genes-08-00095]\]

  miR-143-3p                                    0000435                          osteosarcoma                  doxorubicin                                               d                      \+                                     \[[@B178-genes-08-00095]\]

  miR-101-3p                                    0000099                          osteosarcoma                  cisplatin\                                                u                      −                                      \[[@B179-genes-08-00095]\]
                                                                                                               doxorubicin\                                                                                                            
                                                                                                               methotrexate                                                                                                            

  miR-29b-1                                     MI00000105\                      osteosarcoma                                                                            u                      −                                      \[[@B180-genes-08-00095]\]
                                                (precursor)                                                                                                                                                                            

  miR-33a-5p                                    0000091                          osteosarcoma                  cisplatin                                                 u                      \+                                     \[[@B181-genes-08-00095]\]

  miR-34c-5p                                    0000686                          osteosarcoma                                                                            u                      −                                      \[[@B182-genes-08-00095]\]

  miR-301a-3p                                   0000688                          osteosarcoma                  doxorubicin                                               u                      \+                                     \[[@B183-genes-08-00095]\]

  miR-22-3p                                     0000077                          osteosarcoma                                                                            u                      −                                      \[[@B184-genes-08-00095]\]

  miR-382-5p                                    0000737                          osteosarcoma                                                                            u                      −                                      \[[@B185-genes-08-00095]\]

  miR-193a-5p                                   0004614                          osteo-/ewing sarcoma          cisplatin                                                 u                      −                                      \[[@B186-genes-08-00095]\]

  miR-136-5p                                    0000448                          ovarian                       cisplatin                                                 u                      \+                                     \[[@B187-genes-08-00095]\]

  miR-30a-5p                                    0000087                          ovarian                       cisplatin                                                 u                      −                                      \[[@B188-genes-08-00095]\]

  miR-149-5p                                    0000450                          ovarian                       paclitaxel                                                d                      \+                                     \[[@B189-genes-08-00095]\]

  miR-9-5p                                      0000441                          ovarian                       paclitaxel                                                d                      \+                                     \[[@B190-genes-08-00095]\]

  miR-21-3p                                     0004494                          ovarian                       cisplatin                                                 u                      \+                                     \[[@B191-genes-08-00095]\]

  miR-31-5p                                     0000089                          ovarian                       cisplatin                                                 u                      \+                                     \[[@B192-genes-08-00095]\]

  miR-31-5p                                     0000089                          ovarian                       taxane                                                    u                      −                                      \[[@B193-genes-08-00095]\]

  miR-29b-3p                                    0000100                          ovarian                       paclitaxel                                                d                      \+                                     \[[@B194-genes-08-00095]\]

  miR-200a-3p                                   0000682                          ovarian                       paclitaxel                                                u                      −                                      \[[@B195-genes-08-00095]\]

  miR-506-3p                                    0002878                          ovarian                       cisplatin\                                                u                      −                                      \[[@B196-genes-08-00095]\]
                                                                                                               olaparib                                                                                                                

  miR-433-3p                                    0001627                          ovarian                       paclitaxel                                                u                      \+                                     \[[@B197-genes-08-00095]\]

  miR-186-5p                                    0000456                          ovarian                       cisplatin                                                 u                      −                                      \[[@B198-genes-08-00095]\]

  miR-1307-3p                                   0005951                          ovarian                                                                                 u                      \+                                     \[[@B199-genes-08-00095]\]

  miR-224-5p                                    0000281                          ovarian                       cisplatin                                                 u                      \+                                     \[[@B200-genes-08-00095]\]

  miR-130a-3p                                   0000425                          ovarian                       cisplatin                                                 u                      −                                      \[[@B201-genes-08-00095]\]

  miR-374a-5p                                   0000727                          u                             −                                                                                                                       

  miR-106a-5p                                   0000103                          ovarian                       cisplatin                                                 u                      −                                      \[[@B202-genes-08-00095]\]

  miR-106a-5p                                   0000103                          ovarian                       paclitaxel                                                u                      \+                                     \[[@B203-genes-08-00095]\]

  miR-591                                       0003259                          d                             \+                                                                                                                      

  miR-770-5p                                    0003948                          ovarian                       cisplatin                                                 u                      −                                      \[[@B204-genes-08-00095]\]

  miR-21-5p                                     0000076                          ovarian                       paclitaxel; exosome-driven                                u                      \+                                     \[[@B205-genes-08-00095]\]

  miR-199b-5p                                   0000263                          ovarian                       cisplatin                                                 d                      \+                                     \[[@B206-genes-08-00095]\]

  miR-145-5p                                    0000437                          ovarian                       paclitaxel                                                u                      −                                      \[[@B207-genes-08-00095]\]

  let-7e-5p                                     0000066                          ovarian                       cisplatin                                                 d                      \+                                     \[[@B208-genes-08-00095]\]

  miR-152-3p                                    0000438                          ovarian                       cisplatin                                                 u                      −                                      \[[@B209-genes-08-00095]\]

  miR-128-3p                                    0000424                          ovarian                       cisplatin                                                 d                      \+                                     \[[@B210-genes-08-00095]\]

  miR-484                                       0002174                          ovarian                                                                                 d                      \+                                     \[[@B211-genes-08-00095]\]

  miR-642a-5p                                   0003312                          d                             \+                                                                                                                      

  miR-217                                       0000274                          d                             \+                                                                                                                      

  miR-23a-3p                                    0000078                          ovarian                                                                                 u                      \+                                     \[[@B212-genes-08-00095]\]

  miR-27b-3p                                    0000419                          u                             \+                                                                                                                      

  miR-424-5p                                    0001341                          u                             \+                                                                                                                      

  miR-503-5p                                    0002874                          u                             \+                                                                                                                      

  miR-21-5p                                     0000076                          ovarian                       carboplatin\                                              u                      \+                                     \[[@B213-genes-08-00095]\]
                                                                                                               paclitaxel                                                                                                              

  miR-214-3p                                    0000271                          u                             \+                                                                                                                      

  miR-182-5p                                    0000259                          ovarian                       cisplatin\                                                u                      \+                                     \[[@B214-genes-08-00095]\]
                                                                                                               paclitaxel                                                                                                              

  miR-200c-3p                                   0000617                          pancreatic                                                                              u                      \-                                     \[[@B215-genes-08-00095]\]

  miR-33a-5p                                    0000091                          pancreatic                    gemcitabine                                               u                      \-                                     \[[@B216-genes-08-00095]\]

  miR-17-92 cluster                                                              pancreatic                                                                              d                      \+                                     \[[@B217-genes-08-00095]\]

  miR-221-3p                                    0000278                          pancreatic                    5-fluorouracil                                            u                      \+                                     \[[@B218-genes-08-00095]\]

  miR-1246                                      0005898                          pancreatic                                                                              u                      \+                                     \[[@B219-genes-08-00095]\]

  miR-181b-5p                                   0000257                          pancreatic                    gemcitabine                                               u                      \+                                     \[[@B220-genes-08-00095]\]

  miR-494-3p                                    0002816                          pancreatic                                                                              u                      −                                      \[[@B221-genes-08-00095]\]

  miR-101-3p                                    0000099                          pancreatic                    gemcitabine                                               u                      −                                      \[[@B222-genes-08-00095]\]

  miR-100-5p                                    0000098                          pancreatic (ductal)           gemcitabine                                               u                      \+                                     \[[@B223-genes-08-00095],[@B224-genes-08-00095]\]

  miR-21-5p                                     0000076                          u                             \+                                                                                                                      

  miR-99a-5p                                    0000097                          u                             \+                                                                                                                      

  miR-125b-5p                                   0000423                          u                             \+                                                                                                                      

  miR-138-5p                                    0000430                          u                             \+                                                                                                                      

  miR-210-3p                                    0000267                          u                             \+                                                                                                                      

  miR-31-3p                                     0004504                          d                             \+                                                                                                                      

  miR-330-3p                                    0000751                          d                             \+                                                                                                                      

  miR-378-5p                                    0000731                          d                             \+                                                                                                                      

  let-7a-5p                                     0000062                          pancreatic                    gemcitabine                                               u                      −                                      \[[@B225-genes-08-00095]\]

  miR-205-5p                                    0000266                          pancreatic                    gemcitabine                                               u                      −                                      \[[@B226-genes-08-00095]\]

  miR-506-3p                                    0002878                          pancreatic                                                                              d                      \+                                     \[[@B227-genes-08-00095]\]

  miR-3176                                      0015053                          prostate                      paclitaxel                                                d                      \+                                     \[[@B228-genes-08-00095]\]

  miR-141-3p                                    0000432                          d                             \+                                                                                                                      

  miR-5004-5p                                   0021027                          d                             \+                                                                                                                      

  miR-16-5p                                     0000069                          d                             \+                                                                                                                      

  miR-3915                                      0018189                          d                             \+                                                                                                                      

  miR-488-3p                                    0004763                          d                             \+                                                                                                                      

  miR-23c                                       0018000                          d                             \+                                                                                                                      

  miR-3673                                      0018096                          d                             \+                                                                                                                      

  miR-3654                                      0018074                          d                             \+                                                                                                                      

  miR-32-5p                                     0000090                          u                             \+                                                                                                                      

  miR-606                                       0003274                          u                             \+                                                                                                                      

  miR-381-3p                                    0000736                          u                             \+                                                                                                                      

  miR-429                                       0001536                          u                             \+                                                                                                                      

  miR-708                                       0004926                          renal                         doxorubicin                                               u                      −                                      \[[@B229-genes-08-00095]\]

  let-7b-5p                                     0000063                          renal                         5-fluorouracil                                            u                      −                                      \[[@B230-genes-08-00095]\]

  let-7c-5p                                     0000064                          u                             −                                                                                                                       

  miR-200c-3p                                   0000617                          renal                         docetaxel                                                 d                      \+                                     \[[@B231-genes-08-00095]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

genes-08-00095-t002_Table 2

###### 

Compendium of lncRNAs identified to influence cancer chemoresistance, either as oncogenic lncRNAs or as tumour suppressors. Table keys: u, Upregulated; d, Downregulated; +, Exacerbation; −, Inhibition.

  lncRNA/s involved (Species---*Homo sapiens*)   gene ID (LNCipedia.org---Where Applicable)   Cancer Model             Affected Chemo-Therapy Drugs      Dysregulation Status   Effect on Chemo-Resistance Phenotype   Ref.
  ---------------------------------------------- -------------------------------------------- ------------------------ --------------------------------- ---------------------- -------------------------------------- ---------------------------------------------------
  UCA1                                           UCA1                                         bladder                  cisplatin, gemcitabine            u                      \+                                     \[[@B242-genes-08-00095],[@B243-genes-08-00095]\]
  NONHSAT028712                                  lnc-DGKA-1                                   breast                   doxorubicin                       u                      \+                                     \[[@B244-genes-08-00095]\]
  NONHSAT057282                                  lnc-RP11-677O4.1.1-7                         u                        \+                                                                                              
  NONHSAG023333                                  lnc-TXNDC2-7                                 u                        \+                                                                                              
  ARA                                            lnc-ALG13-7                                  breast                   doxorubicin                       u                      \+                                     \[[@B245-genes-08-00095]\]
  ATB                                            lncRNA-AL589182                              breast                   trastuzumab                       u                      \+                                     \[[@B246-genes-08-00095]\]
  GAS5                                           GAS5                                         breast                   trastuzumab                       d                      \+                                     \[[@B247-genes-08-00095]\]
  XIST                                           XIST                                         breast                   alkylating agents                 u                      \+                                     \[[@B248-genes-08-00095]\]
  53BP1                                          Lnc-TP53BP1-1                                d                        \+                                                                                              
  CCAT2                                          lnc-POU5F1B-8                                breast                   5-fluorouracil                    u                      \+                                     \[[@B249-genes-08-00095]\]
  snaR                                           lnc-BSPH1-1/2                                colon                    5-fluorouracil                    u                      \+                                     \[[@B250-genes-08-00095]\]
  LINC00152                                      LINC00152                                    colon                    oxaliplatin                       u                      \+                                     \[[@B251-genes-08-00095]\]
  SLC25A25-AS1                                   SLC25A25-AS1                                 colorectal                                                 d                      \+                                     \[[@B252-genes-08-00095]\]
  MRUL                                           (NR_024549)                                  gastric                  MDR                               u                      \+                                     \[[@B239-genes-08-00095]\]
  AK022798                                       lnc-TRAF3IP3-3                               gastric                  cisplatin                         u                      \+                                     \[[@B253-genes-08-00095]\]
  PVT1                                           PVT1                                         gastric                  MDR                               u                      \+                                     \[[@B254-genes-08-00095]\]
  LINC-ROR                                       LINC-ROR                                     hepatocellular           sorafenib, doxorubicin            u                      \+                                     \[[@B255-genes-08-00095]\]
  CCAT1                                          lnc-TMEM75-3                                 lung                     docetaxel                         u                      \+                                     \[[@B256-genes-08-00095]\]
  AK126698                                       (LINC00969)                                  lung                     cisplatin                         d                      \+                                     \[[@B257-genes-08-00095]\]
  HOTAIR                                         HOTAIR                                       lung                     MDR                               u                      \+                                     \[[@B236-genes-08-00095],[@B237-genes-08-00095]\]
  GAS5                                           GAS5                                         lung                     EGFR-tyrosine kinase inhibitors   u                      −                                      \[[@B240-genes-08-00095]\]
  UCA1                                           UCA1                                         lung                     EGFR-tyrosine kinase inhibitors   u                      \+                                     \[[@B241-genes-08-00095]\]
  MEG3                                           MEG3                                         lung                     cisplatin                         u                      \+                                     \[[@B258-genes-08-00095]\]
  GAS5                                           GAS5                                         lymphoma (mantle cell)   mTOR inhibitors                   u                      −                                      \[[@B259-genes-08-00095]\]
  N375709                                        (lnc-SRCIN1-1)                               nasopharyngeal           paclitaxel                        d                      −                                      \[[@B260-genes-08-00095]\]
  LINC-ROR                                       LINC-ROR                                     nasopharyngeal                                             u                      \+                                     \[[@B261-genes-08-00095]\]
  TUG1                                           TUG1                                         oesophageal                                                u                      \+                                     \[[@B262-genes-08-00095]\]
  LINC00161                                      LINC00161                                    osteosarcoma             cisplatin                         u                      −                                      \[[@B263-genes-08-00095]\]
  ODRUL                                          FOXC2-AS1                                    osteosarcoma             doxorubicin                       u                      \+                                     \[[@B264-genes-08-00095]\]
  ODRUL                                          FOXC2-AS1                                    osteosarcoma             doxorubicin                       u                      \+                                     \[[@B265-genes-08-00095]\]
  HOTAIR                                         HOTAIR                                       ovarian                  platinum-based drugs              u                      \+                                     \[[@B238-genes-08-00095]\]
  PVT1                                           PVT1                                         ovarian                  cisplatin                         u                      \+                                     \[[@B266-genes-08-00095]\]
  UCA1                                           UCA1                                         ovarian                                                    u                      \+                                     \[[@B267-genes-08-00095]\]
  HOTTIP                                         BCYRN1                                       ovarian                  carboplatin                       d                      \+                                     \[[@B268-genes-08-00095]\]
  HOTTIP                                         BCYRN1                                       pancreatic               gemcitabine                       u                      \+                                     \[[@B269-genes-08-00095]\]
  PVT1                                           PVT1                                         pancreatic               gemcitabine                       u                      \+                                     \[[@B270-genes-08-00095]\]
  MALAT-1                                        MALAT1                                       pancreatic                                                 u                      \+                                     \[[@B271-genes-08-00095]\]
  GAS5                                           GAS5                                         prostate                 mTOR inhibitors                   u                      −                                      \[[@B272-genes-08-00095]\]
  UCA1                                           UCA1                                         breast                   tamoxifen                         u                      \+                                     \[[@B273-genes-08-00095]\]
